These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26620919)

  • 1. A Pilot Study of Antithrombin Replacement Prior to Cardiopulmonary Bypass in Neonates.
    Niebler RA; Woods KJ; Murkowski K; Ghanayem NS; Hoffman G; Mitchell ME; Punzalan RC; Scott JP; Simpson P; Tweddell JS
    Artif Organs; 2016 Jan; 40(1):80-5. PubMed ID: 26620919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-Blind, Randomized, Placebo-Controlled Trial Comparing the Effects of Antithrombin Versus Placebo on the Coagulation System in Infants with Low Antithrombin Undergoing Congenital Cardiac Surgery.
    Jooste EH; Scholl R; Wu YH; Jaquiss RDB; Lodge AJ; Ames WA; Homi HM; Machovec KA; Greene NH; Donahue BS; Shah N; Benkwitz C
    J Cardiothorac Vasc Anesth; 2019 Feb; 33(2):396-402. PubMed ID: 30072263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges with heparin-based anticoagulation during cardiopulmonary bypass in children: Impact of low antithrombin activity.
    Manlhiot C; Gruenwald CE; Holtby HM; Brandão LR; Chan AK; Van Arsdell GS; McCrindle BW
    J Thorac Cardiovasc Surg; 2016 Feb; 151(2):444-50. PubMed ID: 26553458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin-protamine balance after neonatal cardiopulmonary bypass surgery.
    Peterson JA; Maroney SA; Zwifelhofer W; Wood JP; Yan K; Bercovitz RS; Woods RK; Mast AE
    J Thromb Haemost; 2018 Oct; 16(10):1973-1983. PubMed ID: 30016577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Heparin-Resistant Patients with Benefits? Maximizing Biocompatibility in Cardiopulmonary Bypass: Combining ATryn® Recombinant Antithrombin III and Carmeda® Heparin-Bonded Perfusion Circuits: A Case Series.
    Chryssos A; Stroup SJ; Pifer MM; Tawil M; Conrad CG
    J Extra Corpor Technol; 2015 Mar; 47(1):44-7. PubMed ID: 26390679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass.
    Avidan MS; Levy JH; van Aken H; Feneck RO; Latimer RD; Ott E; Martin E; Birnbaum DE; Bonfiglio LJ; Kajdasz DK; Despotis GJ
    J Thorac Cardiovasc Surg; 2005 Jul; 130(1):107-13. PubMed ID: 15999048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heparin-level-based anticoagulation management during cardiopulmonary bypass: a pilot investigation on the effects of a half-dose aprotinin protocol on postoperative blood loss and hemostatic activation and inflammatory response.
    Koster A; Huebler S; Merkle F; Hentschel T; Gründel M; Krabatsch T; Tambeur L; Praus M; Habazettl H; Kuebler WM; Kuppe H
    Anesth Analg; 2004 Feb; 98(2):285-290. PubMed ID: 14742356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged Activated Clotting Time after Protamine Administration Does Not Indicate Residual Heparinization after Cardiopulmonary Bypass in Pediatric Open Heart Surgery.
    Yamamoto T; Wolf HG; Sinzobahamvya N; Asfour B; Hraska V; Schindler E
    Thorac Cardiovasc Surg; 2015 Aug; 63(5):397-403. PubMed ID: 26121380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effects of Steroids on Coagulation Dysfunction Induced by Cardiopulmonary Bypass: A Steroids in Cardiac Surgery (SIRS) Trial Substudy.
    Paparella D; Parolari A; Rotunno C; Vincent J; Myasoedova V; Guida P; De Palo M; Margari V; Devereaux PJ; Lamy A; Alamanni F; Yusuf S; Whitlock R
    Semin Thorac Cardiovasc Surg; 2017 Spring; 29(1):35-44. PubMed ID: 28683994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there evidence that fresh frozen plasma is superior to antithrombin administration to treat heparin resistance in cardiac surgery?
    Beattie GW; Jeffrey RR
    Interact Cardiovasc Thorac Surg; 2014 Jan; 18(1):117-20. PubMed ID: 24014620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial antithrombin-III deficiency during cardiopulmonary bypass: a case report.
    Brinks HJ; Weerwind PW; Verkroost MW; Nováková I; Brouwer MH
    Perfusion; 2000 Nov; 15(6):553-6. PubMed ID: 11131221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and future trends in coagulation management for congenital heart surgery.
    Gottlieb EA; Andropoulos DB
    J Thorac Cardiovasc Surg; 2017 Jun; 153(6):1511-1515. PubMed ID: 28314527
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of the anticoagulation regimen on endothelial-related coagulation in cardiac surgery patients.
    Boldt J; Schindler E; Welters I; Wittstock M; Stertmann WA; Hempelmann G
    Anaesthesia; 1995 Nov; 50(11):954-60. PubMed ID: 8678251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: a randomized, placebo-controlled, multicenter clinical trial.
    Karkouti K; von Heymann C; Jespersen CM; Korte W; Levy JH; Ranucci M; Sellke FW; Song HK
    J Thorac Cardiovasc Surg; 2013 Oct; 146(4):927-39. PubMed ID: 23820174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation.
    Despotis GJ; Levine V; Joist JH; Joiner-Maier D; Spitznagel E
    Anesth Analg; 1997 Sep; 85(3):498-506. PubMed ID: 9296400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coagulation defects in neonates during cardiopulmonary bypass.
    Kern FH; Morana NJ; Sears JJ; Hickey PR
    Ann Thorac Surg; 1992 Sep; 54(3):541-6. PubMed ID: 1510523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of high-dose heparin on inflammatory and coagulation parameters following cardiopulmonary bypass.
    Paparella D; Al Radi OO; Meng QH; Venner T; Teoh K; Young E
    Blood Coagul Fibrinolysis; 2005 Jul; 16(5):323-8. PubMed ID: 15970715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy.
    Ekert H; Brizard C; Eyers R; Cochrane A; Henning R
    Blood Coagul Fibrinolysis; 2006 Jul; 17(5):389-95. PubMed ID: 16788315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biocompatibility of heparin-coated extracorporeal bypass circuits: a randomized, masked clinical trial.
    Muehrcke DD; McCarthy PM; Kottke-Marchant K; Harasaki H; Pierre-Yared J; Borsh JA; Ogella DA; Cosgrove DM
    J Thorac Cardiovasc Surg; 1996 Aug; 112(2):472-83. PubMed ID: 8751516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.